Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

9 Sep 2014
by Working Group

Posted in Announcements, Events, TB Treatment, Uncategorized

Results of Phase III ReMoxTB Clinical Trial Published

Moxifloxacin

Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a [...]

TB Alliance launches landmark Phase 3 clinical trial aimed at shortening duration of TB treatment

TBAlliance

TB Alliance announces STAND, a Phase 3 Clinical Trial aimed at shortening the duration of treatment for drug-sensitive and MDR-TB.

TB R&D Update: Researchers at EPFL create organization to help bring promising new antibiotic, ‘PBTZ169’, to market

PBTZ169

Researchers at EPFL and the Bach Institute in Moscow have discovered an antibiotic effective against sensitive and MDR-tuberculosis. With support from EPFL, the researchers have created Innovative Medicines for Tuberculosis (iM4TB), an organization to help usher the new antibiotic to market.

10 Sep 2013
by Working Group

Posted in TB Drug Development, TB News

Fighting Tuberculosis With FDA Approved Hypertensive Drug Verapamil

ShashankGupta_Lab_Photo on

In a significant finding for millions of TB patients, researchers have recently shown that adjunct chemotherapy with verapamil can accelerate tuberculosis treatment in mouse model.

30 Jul 2013

EMA fails to recommend Otsuka’s Delamanid for MDR TB

otsuka

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) failed to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB). A letter from the Treatment Action Group criticizing this decision is included.

17 Jul 2013
by Working Group

Posted in Announcements, TB Drug Development, TB News

Sequella Acquires Exclusive Worldwide Rights to Pfizer’s Sutezolid

PNU100480

Sequella today announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB).

9 Jul 2013
by Working Group

Posted in Announcements, TB Drug Development, TB News

Otsuka Begins Paediatric MDR-TB Trials

otsuka

Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB). Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a dispersible formulation for use with younger children and infants.

1 Jul 2013
by Working Group

Posted in Action, TB Drug Development, TB News

TAG Releases 2013 Pipeline Report

Click here to access full report

HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

26 Apr 2013
by Working Group

Posted in Announcements, TB Drug Development, TB Pediatrics

Tagline Spring 2013: 3 Articles on TB Research

taglogo

Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access, 2) on adaptive clinical trial designs, and 3) on pediatric drug development needs.

4 Feb 2013

TB R&D Weekly Update: TB Vaccine Efficacy Trial Yields Key Insights and Poor Results

8b5b658d4988a246e72a12cd33f5

The results of the first TB vaccine efficacy trial in over 90 years was released today showing that the vaccine candidate MVA85A when given as a booster did not provide added protection to infants who had already received BCG. The trial adds scientific value to the field and enhances the field’s understanding and ability in conducting large-scale TB vaccine trials. Additional links to TB R&D news are included.